AXSM (NASDAQ) - Axsome Therapeutics Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05464T1043
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. Web URL: https://www.axsome.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for AXSM (NASDAQ) - Axsome Therapeutics Inc

Classification

Market Cap in USD 3,527m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2015-11-19

Ratings

Fundamental -4.14
Dividend -
Performance 5y 7.01
Rel. Performance vs Sector 1.11
Analysts 4.50
Fair Price Total Ret. 79.51
Fair Price DCF todo

Technical

Growth TTM 40.73%
CAGR 5y 84.12%
CAGR / Mean Drawdown 5y 2.39
Sharpe Ratio TTM 0.55
Alpha vs SP500 TTM 18.27
Beta vs SP500 5y weekly 1.16
CAPM 7.84%
Average Daily Range 2m 3.87%
Reversal Oscillator 9.72
Volatility GJR Garch 1y 68.53%
Price / SMA 50 -6.04%
Price / SMA 200 -1.57%
Current Volume 601.6k
Average Volume 20d 677.7k

Dividends

Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%